Sponsored Links
| ImmunoGen, Inc. Announces Positive Clinical Data Presented On IMGN901 In The Treatment Of Multiple Myeloma |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation (abstract #8013) at the ASCO 2011 Annual Meeting in Chicago... Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|